The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra.
We have previously shown that the multi-functional phosphoprotein osteopontin (OPN) is present in the substantia nigra (SN) and that its mRNA and protein expression are up-regulated following toxic insult. We now report the effects of the arginine-glycine-aspartic acid (RGD)-containing peptide fragment of OPN and OPN inactivation on the survival of tyrosine hydroxylase (TH) positive neurones in primary rat ventral mesencephalic (VM) cultures and in SN in the rat. Treatment of VM cultures with the fragment of OPN containing the RGD integrin binding domain did not decrease TH positive cell number, but instead the peptide fragment protected against cell loss induced by both MPP(+) and lipopolysaccharide (LPS). Incorporation of an OPN antibody into VM cultures caused a concentration-dependent loss of TH positive neurones. The OPN antibody also exacerbated MPP(+) - and LPS-induced cell loss at all concentrations tested. In the rat, administration of the RGD-containing peptide fragment of OPN protected TH positive neurones against a mechanically-induced lesion and against 6-hydroxydopamine- and LPS-induced cell loss. The protection against 6-hydroxydopamine toxicity was confirmed in a separate study using stereological analysis. By contrast, stereotaxic injection of the OPN antibody into the SN resulted in a loss of TH positive cells. These results suggest that OPN may be necessary for the survival of TH positive cells in SN but through the RGD-containing peptide fragment may also have neuroprotective properties relevant to Parkinson's disease.
Iczkiewicz
Joanna
J
Neurodegenerative Diseases Research Group, School of Biomedical and Health Sciences, King's College London, London, UK.
Broom
Lauren
L
Cooper
Jonathan D
JD
Wong
Andrew Ming Sham
AM
Rose
Sarah
S
Jenner
Peter
P
D015655:1-Methyl-4-phenylpyridinium / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D053495:Osteopontin / Q000737:chemistry / Q000276:immunology / Q000502:physiology*; D016627:Oxidopamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
D000906:Antibodies; D008070:Lipopolysaccharides; D009842:Oligopeptides; D053495:Osteopontin; C047981:arginyl-glycyl-aspartic acid; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D015655:1-Methyl-4-phenylpyridinium